AI-personalized Medilepsy app to help teens and young adults with epilepsy manage medicines and transition to adult care
AI-Based Mobile Intervention on Medication Non-Adherence and Transition
NA · University of Central Florida · NCT07445074
This trial tests whether an AI-personalized Medilepsy app helps underserved adolescents and young adults with epilepsy (ages 14–24) take their anti-seizure medicines and prepare for adult care better than the standard app.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 14 Years to 24 Years |
| Sex | All |
| Sponsor | University of Central Florida (other) |
| Locations | 2 sites (Orlando, Florida and 1 other locations) |
| Trial ID | NCT07445074 on ClinicalTrials.gov |
What this trial studies
This interventional study compares an AI-personalized version of the Medilepsy chatbot app with a standard non-AI version among underserved adolescents and young adults with epilepsy aged 14–24 in Florida. Participants must be prescribed anti-seizure medications, be English-fluent, own an internet-capable mobile device, and receive outpatient care at participating sites. The apps deliver reminders, education, and transition-readiness support, with primary endpoints focused on medication adherence and transition readiness, secondary endpoints on usability, and exploratory endpoints on language experience. Enrollment and interventions take place at Orlando Health and University of Central Florida outpatient locations, with parental involvement for minors as required.
Who should consider this trial
Good fit: Ideal candidates are underserved adolescents and young adults aged 14–24 with diagnosed epilepsy who are currently prescribed anti-seizure medication, live in Florida, are English-fluent, receive outpatient care, and can use a smartphone with internet.
Not a fit: Patients without a smartphone or internet access, those with severe intellectual disability or inability to operate a mobile device, non-English speakers, inpatients, and pregnant adults (per trial exclusion) are unlikely to benefit from this app-based intervention.
Why it matters
Potential benefit: If successful, the AI-enhanced app could improve medication adherence and transition readiness among underserved youth, potentially leading to better seizure control and smoother transitions to adult care.
How similar studies have performed: Digital reminder and chatbot interventions in other chronic conditions have produced modest adherence improvements, but AI-personalized chatbot approaches specific to epilepsy remain relatively novel with limited prior evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with epilepsy * Currently prescribed anti-seizure medicine (ASMs) * Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage) * Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study * Are between 18-24 years old and able to provide informed consent * Able to read, speak, and write in English * Resides in Florida * Receive outpatient medical services Exclusion Criteria: * They do not own a mobile device with internet access. * They have a history of severe intellectual disability. * They are unable to operate a mobile device (keyboard or touchscreen). * Reside in an in-patient setting. * Adults unable to consent. * Pregnant women (excluded because pregnancy is not relevant to the study focus). * Prisoners.
Where this trial is running
Orlando, Florida and 1 other locations
- Orlando Health — Orlando, Florida, United States (RECRUITING)
- University of Central Florida — Orlando, Florida, United States (RECRUITING)
Study contacts
- Principal investigator: Michelle Tall, PhD, RN, FAES — University of Central Florida
- Study coordinator: Michelle Tall, PhD, RN, FAES
- Email: Michelle.Tall@UCF.edu
- Phone: 4077970555
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.